Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Limitations of current therapies
8 evidence topics · 14 sources
Summary: limitations of cystectomy and of approved bladder-sparing therapies
The EAU guideline states that radical cystectomy is the standard and preferred option for BCG-unresponsive disease and that other treatments must be considered oncologically inferior; it recommends bladder-preserving strategies, preferably within clinical trials, for patients who are not candidates for cystectomy or who decline it. Up to 80% of patients decline or are ineligible for cystectomy. Reported risks of the procedure include morbidity of 50% to 70% and 90-day mortality of approximately 5% (up to 15% in elderly patients), and a manufacturer-funded cost model states that up to one-quarter of patients die and approximately 70% to 80% experience complications within the first year after surgery.
Pembrolizumab, nogapendekin alfa inbakicept-pmln with BCG, and the gemcitabine intravesical system were each approved on the basis of single-arm trials. Their labeled complete response rates were 41% (96 participants), 62% (77 participants), and 82% (83 participants), and no randomized trial compares these agents with each other or with cystectomy. FDA draft guidance states that a randomized controlled trial is preferable and can provide stronger evidence of effectiveness, that time-to-event endpoints are uninterpretable in a single-arm trial, and that a single-arm study cannot assess the contribution of each drug in a combination. For papillary-only disease resected at or before trial entry, the FDA recommends a randomized controlled trial with a time-to-event endpoint. In October 2026, the FDA extended the nogapendekin alfa inbakicept-pmln indication to papillary-only disease by extrapolation from efficacy in disease containing CIS. Labeling for pembrolizumab and the gemcitabine intravesical system is limited to disease with CIS, and pembrolizumab is further limited to patients ineligible for or electing not to undergo cystectomy. Of 31 BCG-unresponsive trials registered on ClinicalTrials.gov, 15 (48%) had enrollment criteria fully consistent with the FDA definition, which the authors state hinders comparisons across agents.
In a meta-analysis of bladder-sparing trials after BCG failure cited by the EAU guideline, pooled 12-month response rates were 24% for trials with more than 2 prior BCG courses and 36% for those with more than 1, and initial response did not predict durable response. Among responders, 46% (pembrolizumab), 58% (nogapendekin alfa inbakicept-pmln with BCG), and 51% (gemcitabine intravesical system) had a duration of response of at least 12 months in the labels. In QUILT-3.032 Cohort A, complete response rates at the 12-, 24-, and 36-month assessments were 47%, 30%, and 16% of 100 participants; in SunRISe-1 Cohort 2, the complete response rate 12 months after treatment initiation was 45.9%. The QUILT-3.032 median duration of response was considered an unreliable estimate because of the limited sample size, small number of events, and substantial censoring. Progression to muscle-invasive disease occurred in 10% (8 participants) in QUILT-3.032 and 8% (7 of 83 evaluable participants) in SunRISe-1 Cohort 2, and each label warns that delaying cystectomy can lead to muscle-invasive or metastatic disease.
Nogapendekin alfa inbakicept-pmln is given with BCG, and TICE BCG is the only approved BCG strain marketed in the U.S. Merck, its sole U.S. manufacturer since 2012, allocates supply to wholesalers and distributors by historical purchasing patterns; in its 2026 letter to health care professionals it reported delays to full startup of a new facility and stated that it will provide an update on timing in the first quarter of 2027. In Medicare claims, BCG use for initial induction therapy decreased from 38.9% before the shortage to 33.0% during it.
Guideline position on radical cystectomy and bladder-sparing therapy
Cystectomy refusal, ineligibility, and perioperative risk
“The current standard of care for BCG-unresponsive high-risk NMIBC is radical cystectomy,” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“which is a life-changing surgery associated with considerable morbidity (50%-70%) and significant impact on quality of life.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Radical cystectomy is also associated with substantial 90-day mortality risk (approximately 5%), particularly in elderly patients (≤15%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Therefore, many patients are unable or unwilling to undergo this procedure, and real-world rates of radical cystectomy for NMIBC are low (<20%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Limitations of approved bladder-sparing therapies stated by trial investigators
“However, these treatments are associated with limited complete response (CR) rates and response durability, systemic or immune-related toxicities, frequent urethral catheterizations, reliance on BCG as combination therapy, and limited physician adoption.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Single-arm trial evidence and FDA trial design recommendations
“An RCT is preferrable and can” (opens the source at this quote in a new tab)
“single-arm study.” (opens the source at this quote in a new tab)
“recurrence-free survival.” (opens the source at this quote in a new tab)
“However, the review of QUILT-3.032 highlighted several challenges in interpreting single-arm data in this disease setting.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One key consideration is that both the primary endpoint of CRR and the key secondary endpoint of DoR may be impacted by heterogeneity across investigators in disease assessment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, a randomized trial with a time-to-event endpoint would be required to demonstrate benefit in patients with papillary-only disease due to the lack of an available response endpoint for resected tumors and variability in the natural history of resected papillary disease, which challenges the interpretation of uncontrolled time-to-event endpoints.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A limitation was the noncomparative cohort design.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The duration of follow-up in the present analysis (median, 20.2 months in Cohort 2 responders) limits the ability to draw firm conclusions regarding long-term efficacy and safety of TAR-200 treatment” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Heterogeneity of trial enrollment criteria
“Of 31 trials, 15 (48%) had inclusion/exclusion criteria that were fully consistent with (inclusive of patients that met) the BCG unresponsive bladder cancer definition.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The most common disease specific exclusion for patients with BCG unresponsive bladder cancer was a requirement for stage Tis (carcinoma in situ, CIS), which pertained to 7 (23%) of trials.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For bladder cancer treating physicians and regulatory bodies, this also hinders comparisons across agents.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Durability of complete response
“At the 12-, 24-, and 36-month response assessments, CR rates were 47% (47 of 100; 95% CI 36.9%-57.2%), 30% (30 of 100; 95% CI 21.2%-40.0%), and 16% (16 of 100; 95% CI 9.4%-24.7%), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At 3, 6, and 12 months after treatment initiation, CR rates were 78.8% (95% CI, 68.6 to 86.9), 58.8% (95% CI, 47.6 to 69.4), and 45.9% (95% CI, 35.0 to 57.0), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For context, among patients treated with pembrolizumab, nadofaragene firadenovec, or NAI plus BCG, 46%-58% had a DOR of ≥12 months, with CIs overlapping.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, given the limited sample size, small number of events, and substantial censoring from approximately 12–15 months, the median DOR in QUILT-3.032 was considered an unreliable estimate.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A post-marketing commitment to better characterize the response duration and risk for progression in all patients was agreed upon with the Applicant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
BCG supply constraints
“Among eligible patients, BCG utilization rates for initial induction therapy decreased 5.9%, from 38.9% (1030 of 2648 patients) in the pre-shortage period, to 33.0% (1756 of 5323 patients) in the shortage period” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote